Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRaME-P1, a registration-enabling trial ...

Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zevra Therapeutics (ZVRA – Research Report) and increased the ...

Pacira ended the third quarter of 2024 with cash, cash equivalents and available-for-sale investments (“cash”) of $453.8 million. Cash provided by operations was $53.9 million in the third quarter of ...

What to watch for: INFLECTION IN IMPRESSION GROWTH: On Wednesday, JMP Securities upgraded ... adverse impact on 2025 revenue. OUTLOOK: During the lastearnings conference call Snap said it saw ...

Haemonetics has set its FY25 guidance at $4.45 to $4.75 EPS and its FY 2025 guidance at 4.450-4.750 EPS.Individual that are ...

Welcome to GSI Technology’s Second Quarter Fiscal 2025 Results ... with the Securities and Exchange Commission. Additionally, I have also been asked to advise you that this conference call ...

JMP Securities updated their EPS estimates for Schwab, forecasting $3.11 for 2024 and $4.38 for 2025. The firm anticipates ... financial services market. 4. Technology and personalization: Schwab ...

“The work we have completed this year positions us to enter 2025 from a new place of focus ... career includes senior leadership roles at JMP Securities, Inc., Deutsche Bank Securities Inc ...

With us today is OptimizeRx's Chief Executive Officer, William Febbo. He is joined by Chief Financial Officer, Ed Stelmakh; President, Steve Silvestro; General Counsel, Marion Odense-Ford; and Senior ...

Operator Good morning and welcome to the ODDITY's third quarter 2024 earnings conference call. Today's call is being recorded ...

Estimates for 2024 and 2025 EPS are set at $13.00 ... October 15, 2024: JMP Securities reiterates Market Outperform rating with a price target of $145. September 23, 2024: JMP Securities maintains ...

JMP Securities analyst Andrew Boone reiterated ... shares trading at a price-to-earnings ratio of 20x based on fiscal 2025 estimates. The antitrust risks and AI-related risks keep the analyst ...